| Log in

Ranbaxy to pay $40M to settle Texas litigation

16 October, 2014

Daiichi Sankyo-controlled Indian drug major Ranbaxy Laboratories Ltd, which awaits a regulatory clearance to go ahead with a proposed merger with Sun Pharma, has decided to settled the litigation concerning its participation in the Texas Medicaid Program by paying $39.75 million in a series of tranches through August 2015 to the state of Texas (US), as per a company statement.

“The claims at issue related exclusively to the manner in which Ranbaxy has historically reported pricing data to Texas Medicaid for certain of its drugs. As has been widely reported, the State of Texas has brought nearly identical claims against virtually every other major pharmaceutical manufacturer in the US,” it stated.

Ranbaxy settled the matter to avoid any further distraction and uncertainty of continued litigation.

Besides this, it also stated that it is terminating its GDR programme.

(Edited by Joby Puthuparampil Johnson)


Leave Your Comment
Ranbaxy gets US FDA approval to sell generic version of Novartis’ heart drug

Ranbaxy gets US FDA approval to sell generic version of Novartis’ heart drug

Jasleen Kaur Batra 3 years ago
Daiichi Sankyo-controlled Indian drug major Ranbaxy Laboratories Ltd has...
Ranbaxy receives patent challenge notice from Watson Laboratories

Ranbaxy receives patent challenge notice from Watson Laboratories

TEAM VCC 4 years ago
Indian pharma major Ranbaxy Laboratories Ltd, which has sole marketing rights of...
Deal of the month: Sun Pharma to acquire Ranbaxy

Deal of the month: Sun Pharma to acquire Ranbaxy

Lohit Jagwani 4 years ago
Deal: India’s largest drug maker by market value Sun Pharmaceutical Industries...
No Comments

Ranbaxy to pay $40M to settle Texas litigation

Powered by WordPress.com VIP